NewsRoom Articles - Page 79 of 154 - PsychedelicNewsWire (PNW)

FridayNov 12, 2021 12:30 pm

Psychedelics May Play a Key Role in End-of-Life Care

Psychedelic drugs may revolutionize the health-care sector, in particular psychiatric treatment and end-of-life care, as more research on these substances is conducted. Substances such as ketamine, psilocybin, MDMA and LSD, which are still illegal in most parts of the country, have shown potential in the treatment of various mental health conditions including anxiety, depression, post-traumatic stress disorder and addiction. The potential of the psychedelic space has been noticed not only by researchers but also by venture capitalists and other investors who have been injecting billions into this burgeoning market in the hopes of getting it off the ground. Some of…

FridayNov 12, 2021 12:14 pm

Recent Sector News Reveals Positive Data in Psychedelic Treatments For Depression as Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Nears Launch of Synthetic Psilocybin Trials

Pharmaceutical company Tryp Therapeutics is developing a proprietary synthetic hallucinogen as potential medical solutions for select unmet health needs, with a focus on taking psychedelic therapeutics beyond mental health The company recently attended the Wonderland: Miami where Compass Pathways unveiled highly anticipated data from their Phase 2b trial in treatment-resistant depression Tryp’s Chairman and CEO Greg McKee served on a panel at Wonderland: Miami discussing the potential of synthetic psilocybin in chronic pain indications and the importance of supporting industry wins Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) Chairman and CEO Greg McKee recently participated in Microdose’s Wonderland: Miami conference as…

ThursdayNov 11, 2021 12:32 pm

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Launches Transformative Training Program for Psychedelic Facilitators

The EMBARK program represents the broad spectrum of ways in which therapeutic benefits might be experienced Program offers psychedelic clinical trial facilitators foundational training to provide skillful, ethical care to participants receiving psychedelic treatment EMBARK is built around open architecture to support varieties of psychedelic experience within a coherent therapeutic framework In a climate where psychedelic treatments are increasing in usage and acceptance, the importance of providing support and guidance in the space becomes even more important. With that in mind, Cybin (NEO: CYBN) (NYSE American: CYBN) has launched its proprietary EMBARK Psychedelic Facilitator Training Program (https://ibn.fm/3lzkp). Named for the program’s…

ThursdayNov 11, 2021 12:00 pm

Voters in Detroit Pass Initiative to Decriminalize Psychedelic Substances

Voters in the city of Detroit have passed a ballot measure that will decriminalize psychedelic substances. Detroit is the latest city to enact the reform in the country. Unofficial results released last week showed that the initiative led by a 61% margin, with all precincts reporting their data. The measure stipulates that the city will decriminalize the therapeutic use and personal possession of entheogenic plants by individuals aged 18 and above, as permitted under the law in the state of Michigan. This is in addition to making the therapeutic use and personal possession of entheogenic plants the lowest law-enforcement priority…

WednesdayNov 10, 2021 11:52 am

Psychedelics Sector Attracts More Investment as Mental Health Conditions Escalate

The burden of mental health conditions has grown significantly these past few years, affecting not only the health of individuals but also the economies of most countries around the globe. The prevalence of these disorders has been exacerbated by the coronavirus pandemic, making the already global issue a priority that requires an immediate solution. Current treatments for different mental health conditions have adverse side effects and aren’t effective in every individual, which makes the need for alternative treatment options even greater. Research has shown that psychedelic substances such as ketamine, psilocybin and LSD possess the potential to treat conditions, including…

TuesdayNov 09, 2021 11:45 am

Overview of Major Sectors Making Up Psychedelics Industry

The psychedelics industry has grown tremendously these last few years, offering new opportunities for investors interested in this space. The potential for the substance to revolutionize the field of medicine has prompted a significant increase in the capital being injected into the multibillion dollar industry, which has facilitated further development. Below is an overview of the major sectors making up this industry. R&D and Clinical Trials This refers to clinical and/or research and development trials that involve psychedelic substances. Currently, there are more than 12 companies conducting phase 2 clinical trials on psychedelic drug candidates and a nonprofit called MAPS…

MondayNov 08, 2021 2:00 pm

Italian Activists Submit More than 600,000 Signatures for Psychedelic Referendum

Last week, activists in Italy submitted more than 600,000 signatures for a referendum to legalize cannabis cultivation as well as the growing of other psychoactive fungi and plants such as magic mushrooms. The reform campaign hopes that with these signatures, their measure, which was filed in September, will be brought before voters next year. The activists were able to collect a high number of signatures because of a change in policy that permitted them to gather signatures in person as well as online. It should be noted that before the measure is brought before the voters, some steps need to…

FridayNov 05, 2021 1:15 pm

UK Prime Minister Boris Johnson to Consider Rescheduling Psilocybin

Psilocybin is a naturally occurring active hallucinogenic compound found in magic mushrooms, which is consumed for its hallucinogenic effects. Recently, Crispin Blunt, a member of the Conservative Party in the United Kingdom, urged UK Prime Minister Boris Johnson to review the laws on psychedelics, particularly psilocybin, and allow more studies on the substance’s therapeutic qualities to be conducted. Blunt explained that psilocybin possessed significant potential for the treatment of various mental health disorders, including addiction, trauma and depression. Research has also found that psilocybin may be used to manage treatment-resistant depression as well as anxiety with researchers also looking into…

FridayNov 05, 2021 9:00 am

Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Validates its AI-Driven Drug Discovery Program with Successful Synthesis of Novel Tryptamine; Confirms Participation in the Wonderland: Miami Psychedelic Medicine Business Event

Mydecine just announced the successful synthesis of a novel psilocin analogue, a tryptamine The achievement adds to the company’s library of patent-pending tryptamines for medical use and therapy, and is seen as verifying the value of Mydecine’s AI-driven drug discovery program Mydecine has also confirmed its participation in the Wonderland: Miami psychedelic medicine event scheduled for November 8-9, 2021, where the company will share its recent research advancements and goals going forward Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) just announced the successful synthesis of a novel psilocin analogue, a tryptamine, that has proven to have improved pharmaceutical properties (https://ibn.fm/I2lX7).…

ThursdayNov 04, 2021 12:49 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Marks Another Significant Milestone with IND Application for Fibromyalgia Phase 2a Clinical Trial

Tryp just filed an IND with the FDA for its TRP-8802 clinical candidate for its Phase 2a clinical trial The trial is set to commence in 2022, subject to a favorable review by the FDA The study will be conducted in collaboration with the University of Michigan and will aim at evaluating the safety and clinical utility of psilocybin for fibromyalgia Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) just announced its submission of an Investigational New Drug (“IND”) application to the United States Food and Drug Administration (“FDA”) for its TRP-88802 clinical candidate. This application follows the commencement of Tryp’s Phase…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000